Company Information
USD
2.27
- (-0.9%)
NASDAQ:ORMP, ORAMED PHARMACEUTICALS INC.
Industry: Biotechnology
End of Day: 9 May 2025 GMT-4
Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.
Address
1185 Avenue of the Americas
Third Floor
Website
Classification
Sector
Healthcare
Industry Group
Biotechnology
Industry
Biotechnology
Key Executives
Mr. Benjamin Shapiro
Director
Dr. Daniel Aghion
Director
Mr. Leonard Sank
Director
Dr. Miriam Kidron,PhD
Chief Scientific Officer/Director
Mr. Nadav Kidron
CEO/Chairman of the Board/Director/President
Mr. Joshua Hexter
COO/Other Executive Officer
Dr. Arie Mayer, PhD
Director
Mr. David Silberman
CFO/Chief Accounting Officer/Treasurer
Mr. Michael Rabinowitz
Other Executive Officer
Mr. Netanel Derovan
Chief Legal Officer/Secretary
Ownership
Institution Holdings
BML Capital Management LLC
1,261,559 (3.127%)
Murchinson Ltd.
1,050,000 (2.603%)
BOOTHBAY FUND MANAGEMENT, LLC
525,001 (1.301%)
Renaissance Technologies Corp
341,073 (0.846%)
Rathbone Brothers PLC
289,803 (0.718%)
Two Sigma Advisers, LLC
283,600 (0.703%)
Bank of America Corp
271,403 (0.673%)
Two Sigma Investments LLC
157,330 (0.390%)
Squarepoint Ops LLC
117,276 (0.291%)
BlackRock Inc
87,758 (0.218%)
Funds Holdings
Harel HTF TA All-Share IL
3,940 (0.010%)
Make Smart Investment Choices